# Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer

Source: https://onco.cc/trials/nct04906395/  
OnCo record `nct04906395` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Tamoxifen and Exemestane in advanced solid tumours, run by Tolmar Inc., active and no longer recruiting.

## Summary

Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer is a phase 3 interventional study registered as NCT04906395 by Tolmar Inc., with 250 participants enrolled, started 2021-07-01 and due to reach its primary completion in 2026-04-30. Interventions recorded: TOL2506, Tamoxifen, Letrozole Tablets, Anastrozole Tablets and Exemestane Tablets.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04906395
- Phase: 3
- Setting: Phase 3,Single Arm,Open-Label Study Evaluating Ovarian Suppression Following 3 Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination With Endocrine Therapy in Premenopausal Subjects With Hormone-Receptor-Positive (HR+),Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
- Sponsor: Tolmar Inc.
- Enrolled: 250

## Sources

- ClinicalTrials.gov NCT04906395: https://clinicaltrials.gov/study/NCT04906395

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Exemestane](https://onco.cc/drugs/exemestane/), [Tamoxifen](https://onco.cc/drugs/tamoxifen/)
- companies: [Tolmar](https://onco.cc/companies/tolmar/)

---
JSON: https://onco.cc/api/v1/entities/nct04906395.json